more patients who received the new therapy suffered from side effects .
 doctors have tried to determine which patients truly need it rather than just giving the drugs to everyone with hepatitis c. only 20 percent to 30 percent of people with chronic infections develop cirrhosis , liver failure or cancer .
 because of the risks of treatment , and its partial success rate , hoofnagle said .
 u.s. doctors say a combination of two virus-fighting drugs has proved considerably more effective against chronic hepatitis c infections than the standard single medicine .
 rebetron , which might seem a stroke of marketing genius to a drug company , looked like a dangerous precedent to people with hepatitis c. many .
 researchers in canada find new combination of drugs to treat the disease .
 chen zhangliang , the 35-year-old vice-president of beijing university , declared at a seminar here today that recombinant a-1b interferon was approved for production by the ministry of public health in april this year .
 china 's first genetic engineering drug to be put into mass production in the biotechnology section of the country 's `` 863 hi-tech plan '' intron is the maker of intron a -lrb- interferon -rrb- and rebetol -lrb- ribavirin -rrb- .
 the drugs used together _ at a cost of $ 300 a week _ to rid the body of the chronic c virus in some patients .
 intravenous drug use , tattoos and body piercing would be an invitation to a slow-growing virus .
 study : 2.7 million americans carry hepatitis c virus .
 making it the most common blood-borne infection in the united states .
 people who inject illegal drugs or engage in unprotected sex account for most people .
 people who had blood transfusions before mid-1992 also are at risk . schering-plough has been the sole source of ribavirin , sold only as part of a kit that also include 's proprietary brand of interferon .
 data from three large clinical studies showed a smaller proportion of chronic hepatitis b patients treated with zeffix progressed to cirrhosis , or liver scarring .
